Post Profile

Court Orders Johnson & Johnson To Pay $1.2 Billion In Deceptive Marketing Case

Johnson & Johnson and a subsidiary have to pay for the way it marketed antipsychotic drug Risperdal, neglecting to mention its side effects while claiming it was safer and worked better than the competition. In Arkansas, one of 11 states in which J&J has faced legal battles over the drug, a judge ordered the company to pay $1.2 billion to make up for its alleged sins. CNNMoney reports the companies' allegedly deceptive practices caused government-subsidized healthcare services to pay for the drug, which is believed to put patients at risk of diabetes and neurological problems.
read more


Related Posts

J&J Pays $2.2B Over Charges Of Improper Risperdal Marketing

Medical / Pharmaceutical : Pharmalot

After two years of negotiations, Johnson & Johnson and its subsidiaries have agreed to pay more than $2.2 billion to resolve criminal and civil lawsuits that alleged the healthcare giant illegally marketed its Risperal antipsychotic...

Possible billions sought in drug marketing suit | The Post and Courier, Charleston SC - News, Sports, Entertainment

Medical / Pharmaceutical : PharmaGossip

COLUMBIA -- It's now up to a Spartanburg County judge to decide how much a Johnson & Johnson subsidiary should pay South Carolina for deceptive marketing of an antipsychotic drug. If the judge agrees with attorneys for the state, th...

J&J Must Pay Louisiana $257.7 Million Over Risperdal Marketing Practices - Bloomberg

Medical / Pharmaceutical : PharmaGossip

Johnson & Johnson must pay $257.7 million to the state of Louisiana for making misleading claims about the safety of the company’s Risperdal antipsychotic drug, a jury concluded. Jurors in state court in Opelousas, Louisiana, found ...


Medical / Pharmaceutical : PharmaGossip

LITTLE ROCK, Ark. (AP) -- The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of the antipsychotic drug Risperdal.The court ruled tha...

J&J Ordered to Pay $327 Million Over Deceptive Risperdal Marketing Claims - Bloomberg

Medical / Pharmaceutical : PharmaGossip

J&J Ordered to Pay $327 Million Over Deceptive Risperdal Marketing Claims - Bloomberg: "A Johnson & Johnson (JNJ) unit was ordered by a South Carolina judge to pay more than $327 million in penalties for deceptively marketing the an...


Copyright © 2016 Regator, LLC